Evidence map›Paper›PMID 35631059›Full record

ReviewPathogens (Basel, Switzerland)2022

The Evolutionary Dance between Innate Host Antiviral Pathways and SARS-CoV-2.

Saba R Aliyari, Natalie Quanquin, Olivier Pernet, Shilei Zhang, Lulan Wang, Genhong Cheng

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Saba R AliyariDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Natalie QuanquinDepartment of Pediatrics, Division of Infectious Diseases, Children's Hospital Los Angeles, Los Angeles, CA 90027, USA.
Olivier PernetEnViro International Laboratories, Los Angeles, CA 90025, USA.
Shilei ZhangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Lulan WangDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.
Genhong ChengDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA 90095, USA.

Funding

Viral Mediated Type I Interferon InductionR01AI069120 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHENG, GENHONG · 2006 to 2021
$6.0M
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infectionR01AI158154 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI JUNG, MICHAEL E · 2020 to 2025
$1.9M
NIAID NIH HHS R01 AI069120NIAID NIH HHS R01 AI158154
6 · The paper itself

Abstract

Compared to what we knew at the start of the SARS-CoV-2 global pandemic, our understanding of the interplay between the interferon signaling pathway and SARS-CoV-2 infection has dramatically increased. Innate antiviral strategies range from the direct inhibition of viral components to reprograming the host's own metabolic pathways to block viral infection. SARS-CoV-2 has also evolved to exploit diverse tactics to overcome immune barriers and successfully infect host cells. Herein, we review the current knowledge of the innate immune signaling pathways triggered by SARS-CoV-2 with a focus on the type I interferon response, as well as the mechanisms by which SARS-CoV-2 impairs those defenses.

Indexed as

COVID-19innate immunityinterferonSARS-CoV-2

Identifiers

PMID35631059
PMCPMC9147806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.